RxDoctor Payments DataLook up a doctor →

Sixto Perez, MD

Hematology & Oncology · San Juan, PRNPI 1649240110

Payments from drug & device makers

$34,753in general payments, 2019–2025

Across 1,086 payments — averaging $32.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$7K
  • Johnson & Johnson$5K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Merck$4K
  • AstraZeneca$2K
  • AbbVie$2K
  • plus $11K from 42 others

What the payments were for

  • Consulting fees$3,50510%
  • Speaking & faculty fees$8,02523%
  • Travel & lodging$120%
  • Food & beverage$22,53565%
  • Education$6762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,753 in reported general payments places this provider in the 70th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$415,356
Medicare patients
71
Services billed
10,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib33$561,776
KisqaliRibociclib Succinate28$499,168
JakafiRuxolitinib Phosphate18$204,826
RetacritEpoetin Alfa-Epbx35$42,260
Abiraterone Acetate22$29,438
Imatinib Mesylate23$9,083
Anastrozole212$3,333
Hydroxyurea80$2,147
Dexamethasone55$1,341
Megestrol Acetate11$999
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen28$739
Ondansetron OdtOndansetron46$602
Letrozole23$232
Omeprazole41$214
Prednisone20$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$17$561,77633 claims
NovartisKisqali$924$499,16828 claims
Incyte CorporationJakafi$485$204,82618 claims
PfizerRetacrit$240$42,26035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →